Alzheimer's Research UK

Momentum in Alzheimer's Research Guided by the Biology of Aging to be Highlighted in Session Moderated by Alzheimer's Drug Discovery Foundation at 2023 Clinical Trials on Alzheimer's Disease Conference

Retrieved on: 
Tuesday, October 17, 2023
Fillit, Momentum, Drug development, Amyloid, ET, Ageing, Alzheimer's Drug Discovery Foundation, Drug, Therapy, Doctor of Philosophy, Entrepreneurship, Inflammation, Research, Emerging, Boston Park Plaza, Plasma, Denali, Medicine, Biology, Brain, Cancer, Path, Fujirebio, Alzheimer's Research UK, Pharmaceutical industry, Medical imaging, Medical device, Alzheimer's disease, MD, Disease

NEW YORK, Oct. 17, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) will be moderating a session, "Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease," at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference, which will be held October 24th through 27th at Boston Park Plaza in Boston, Massachusetts.

Key Points: 
  • This session will highlight the biology of aging and promising drugs in the pipeline that are targeting the many underlying aging pathologies contributing to the onset of Alzheimer's.
  • This is timely, as 75% of Alzheimer's drugs in clinical trials are exploring novel targets beyond amyloid and tau.
  • The session will also feature innovative research on regenerative therapies for Alzheimer's as well as novel approaches for targeting inflammation.
  • The panel will discuss the strategic investments needed to accelerate the recent momentum in the field, which is critical for fast-tracking the next generation of Alzheimer's therapeutics.

New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced

Retrieved on: 
Friday, June 30, 2023
Pressure, Maintenance, LifeArc, Partnership, University, Therapy, Life, Doctor of Philosophy, Speech, Public, Neurodegenerative disease, University of Edinburgh, Health, Ageing, Alzheimer's Research UK, Quality of life, ML, Research, Genomics, Biomarker, Mentorship, HDR, Disorder, Dementia, Alzheimer's disease, Digital technology, HIV disease progression rates, Patient, Orangi Pilot Project, Machine learning, Algorithm, Artificial intelligence, Drug discovery, Gates Ventures, Diagnosis, AI, Neurology, Disease, Pharmaceutical industry, Industrial design, Medical device, Nursing, Eisai

- NEURii collaboration builds on Eisai's extensive experience in delivering innovative treatments in neurology and supports ongoing contributions to the global digital health ecosystem.

Key Points: 
  • - NEURii collaboration builds on Eisai's extensive experience in delivering innovative treatments in neurology and supports ongoing contributions to the global digital health ecosystem.
  • TOKYO, HATFIELD, SEATTLE, LONDON, and EDINBURGH, June 30, 2023 - (JCN Newswire) - Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement.
  • NEURii will focus its initial efforts to develop data and digital solutions to complement approved treatment options for patients and solve issues related to the prediction, prevention, management, and treatment of dementia related disorders.
  • It is envisaged that NEURii partners will explore further opportunities to scale up the program developing digital health solutions worldwide.

UK Dementia Research Institute: NEW CAMPAIGN 'WILD & PRECIOUS' LAUNCHES TO CREATE AWARENESS OF HOW DEMENTIA DISPROPORTIONATELY AFFECTS WOMEN

Retrieved on: 
Wednesday, April 5, 2023
Summer, Impact, Life, Museum of Memory and Human Rights, Alzheimer's Research UK, Lou Ruvo Center for Brain Health, Woman, Statistics, Human, Research, Brain, Butterfly, Alzheimer's disease, DRI, Risk, Knowledge, Death, Disease, Residential care, Birth control, Cryptocurrency, Entertainment, Medical imaging, Blockchain, Dementia

LONDON, April 5, 2023 /PRNewswire/ -- A ground-breaking new campaign called 'Wild & Precious' launches this week (5 April) to raise awareness of dementia's impact on women, supported by the UK Dementia Research Institute (UK DRI). The project focuses on the cherished memories from incredible women living with the illness, women who are carers, and women who have experienced the disease via loved ones. These stories are a celebration of life, but also outline the impact dementia has on their lives.

Key Points: 

Progress in New Alzheimer's Therapeutics Based on Biology of Aging Highlighted in Symposium Hosted by Alzheimer's Drug Discovery Foundation (ADDF) at AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Dis

Retrieved on: 
Tuesday, March 21, 2023
Fillit, Reverse-path forwarding, Swedish Exhibition & Congress Centre, LSP, Investment, Drug discovery, Disease, Alzheimer's Drug Discovery Foundation, Ageing, Alzheimer's Research UK, Dementia, Cancer, Cognition, MBA, Research, Brain, Doctor of Philosophy, ARUK, Organization, DSM-IV codes, EQT, International Conference on Emerging Infectious Diseases, Homogeneity and heterogeneity, Wake Forest School of Medicine, Drug development, Gates Ventures, Biology, Entrepreneurship, AD, Building a Future, Therapy, Conference, Pharmaceutical industry, Management, Medical imaging, Alzheimer's disease, MD

NEW YORK, March 21, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation will host a symposium, "Building the Future: Novel Approaches and Innovations in Alzheimer's Research" at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders, March 28th through April 1st at the Swedish Exhibition & Congress Centre in Gothenburg, Sweden.

Key Points: 
  • This symposium encompasses two sessions.
  • The second session, "Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease," focuses on the biology of aging and promising drugs in the pipeline that target a host of underlying pathologies that contribute to Alzheimer's disease.
  • It features presentations on research, including novel senolytics and repurposing programs, as well as prevention approaches for Alzheimer's and related dementias.
  • These diverse approaches reflect the current Alzheimer's pipeline, where 75% of drugs in clinical trials focus on non-amyloid and tau targets according to a recent report.

World Hearing Day 2023: Amplifon Supports the World Health Organization’s Commitment to Early Diagnosis by Promoting Free Screening Tests

Retrieved on: 
Friday, March 3, 2023
Health Technology, Health, Other Health, Medical Devices, Risk, Kool-Aid, Hearing, Emotion, World Health Organization, Diagnosis, Huber loss, Amplifon, World Hearing Day, Alzheimer's Research UK, Johns Hopkins Bloomberg School of Public Health, WHO, Multimedia, Hearing loss, Research, Dementia, Sound, Public health, Dentistry, Pharmaceutical industry

This was revealed by the World Health Organization (WHO) on the occasion of World Hearing Day 2023.

Key Points: 
  • This was revealed by the World Health Organization (WHO) on the occasion of World Hearing Day 2023.
  • The theme of this year’s edition is the accessibility of hearing care for all, building on a greater awareness of the diagnosis and treatment of hearing disorders.
  • View the full release here: https://www.businesswire.com/news/home/20230303005296/en/
    World Hearing Day 2023: Amplifon Supports the World Health Organization’s Commitment to Early Diagnosis by Promoting Free Screening Tests (Photo: Business Wire)
    To support the World Health Organization’s commitment, Amplifon Americas, made up of more than 1,200 employees in the U.S. dedicated to serving the diverse needs of its customers through two unique and independent brands: Miracle-Ear, with more than 1,500 locations nationwide, and Amplifon Hearing Health Care, with more than 6,000 clinics across the country, is promoting an awareness campaign, offering free hearing tests in all its Miracle-Ear stores.
  • Amplifon Americas, a division of Amplifon Group, is a leading provider of hearing health care solutions in the U.S. and Canada.

Gene Mutation May Explain Brain Cell Plaque Buildup in Alzheimer's Disease

Retrieved on: 
Wednesday, November 30, 2022
Doctor of Philosophy, Cure Alzheimer's Fund, National Institutes of Health, Cell, NYU Langone Health, Mutation, Gene, Hasel, Glaucoma, New York University Grossman School of Medicine, DNA, Bacteria, Brain, Enzyme, Alzheimer's Research UK, INPP5D, Physiology, Alzheimer's Association, Inflammation, Rockefeller Neuroscience Institute, Microglia, Parkinson's disease, NYU, Plaque, Icahn School of Medicine at Mount Sinai, Neurodegeneration, Multiple sclerosis, Journal, Mouse, Ophthalmology, Virus, Monroe Dunaway Anderson, Huntington's disease, Research, Human, Mount Sinai, BA, Vaccine, Pharmaceutical industry, Medical imaging, Antibiotics, Neuroscience, Dementia, MD, Shelly Liddelow, Alzheimer's disease, Medicine

The buildup of such clumps, also called plaque, sets off an immune response that can kill brain cells and may lead to the dementia associated with Alzheimer's disease.

Key Points: 
  • The buildup of such clumps, also called plaque, sets off an immune response that can kill brain cells and may lead to the dementia associated with Alzheimer's disease.
  • The new findings may offer a potential new target for therapies that directly affect the gene mutation, according to the study authors.
  • Notably, this cluster is known to produce molecules that trigger inflammation in Parkinson's disease, Huntington's disease, and various forms of dementia.
  • They compared these findings to previous research in humans with Alzheimer's disease, observing the same genetic changes in the gene cluster linked to plaque.

The Rainwater Charitable Foundation announces partnership with drug discovery teams at the University of Oxford

Retrieved on: 
Thursday, June 2, 2022
K-12, University, Animation, Research, Alzheimer's Research UK, Business, ARUK, Disease, Neurodegeneration, Partnership, Tauopathy, RCF, Divisions of the University of Oxford, Alzheimer's Drug Discovery Foundation, CMD, Therapy, Drug discovery, Computational chemistry, Patient, Nuffield Department of Population Health, ADME, Dementia, United States dollar, Heart, Rain, Center, Pharmaceutical industry, Alzheimer's disease

FORT WORTH, Texas  , June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford. This partnership intends to accelerate the development of novel therapeutics aimed at the treatment of tauopathies, a group of progressive neurodegenerative diseases.

Key Points: 
  • FORT WORTH, Texas, June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford.
  • The deep knowledge in basic discovery biology and tauopathy mechanisms derived from the Tau Consortium principal investigators will complement the drug discovery expertise of the ARUK-ODDI team.
  • The Rainwater Charitable Foundation (RCF) was created in the early 1990s by renowned private equity investor and philanthropist Richard E. Rainwater.
  • The Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) is a research team within the Centre for Medicines Discovery (CMD) at the University of Oxford.

The Rainwater Charitable Foundation announces partnership with drug discovery teams at the University of Oxford

Retrieved on: 
Thursday, June 2, 2022
K-12, University, Animation, Research, Alzheimer's Research UK, Business, ARUK, Disease, Neurodegeneration, Partnership, Tauopathy, RCF, Divisions of the University of Oxford, Alzheimer's Drug Discovery Foundation, CMD, Therapy, Drug discovery, Computational chemistry, Patient, Nuffield Department of Population Health, ADME, Dementia, United States dollar, Heart, Rain, Center, Pharmaceutical industry, Alzheimer's disease

FORT WORTH, Texas, June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford. This partnership intends to accelerate the development of novel therapeutics aimed at the treatment of tauopathies, a group of progressive neurodegenerative diseases.

Key Points: 
  • FORT WORTH, Texas, June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford.
  • The deep knowledge in basic discovery biology and tauopathy mechanisms derived from the Tau Consortium principal investigators will complement the drug discovery expertise of the ARUK-ODDI team.
  • The Rainwater Charitable Foundation (RCF) was created in the early 1990s by renowned private equity investor and philanthropist Richard E. Rainwater.
  • The Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) is a research team within the Centre for Medicines Discovery (CMD) at the University of Oxford.

Alzheimer's Drug Discovery Foundation Awards Dr. Miia Kivipelto Esteemed Melvin R. Goodes Prize

Retrieved on: 
Friday, October 29, 2021
Fillit, Drug discovery, Alzheimer's Drug Discovery Foundation, MD, Dementia, Research, Cognitive deficit, Metformin, University, Industry, Warner–Lambert, Board of directors, University of Eastern Finland, Founder, United States House Permanent Select Committee on Aging, Alzheimer's Research UK, Military, Geriatrics, Exercise, Imperial College London, Founding, Ageing, Board, CEO, Diet, Courage, Diabetes, Disability, Development, Selection, Melvin, Karolinska University Hospital, Pharmaceutical industry

NEW YORK, Oct. 29, 2021 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) has named Dr.Miia Kivipelto as the recipient of the 2021Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery.

Key Points: 
  • NEW YORK, Oct. 29, 2021 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) has named Dr.Miia Kivipelto as the recipient of the 2021Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery.
  • The Goodes Prize, named for Melvin R. Goodes, a distinguished leader in the pharmaceutical industry, is awarded each year to an innovative researcher who has made a significant and lasting impact in the Alzheimer's field.
  • The Melvin R. Goodes Prize is named in honor of the courage, legacy and research advocacy of Mr. Goodes, former Warner-Lambert Chairman and CEO and honorary member of the ADDF's Board of Governors.
  • The Goodes Family Foundation committed$750,000to fund the Goodes Prizes for 10 years, and the ADDF matched that contribution.

Cumulus Neuroscience Appoints Dr Ruth McKernan CBE as Chair

Retrieved on: 
Tuesday, September 14, 2021
Pfizer, Innovation, Knowledge, SME, GlaxoSmithKline, Human resource policies, Board, Central nervous system, CEO, Medical Research Council, DDF, Technology, Dementia, Chair, Neuroscience, Cancer Research UK, Patient, Company, Lists of diseases, Clinical trial, Cumulus cloud, Alzheimer's disease, HIV disease progression rates, Association, Therapy, Central Waqf Council, CBE, Science, Norwest Venture Partners, CNS, LifeArc, Alzheimer's Research UK, Time, Research, Medical Research Council (United Kingdom), Department for Business, Innovation and Skills, Pharmaceutical industry, Medical imaging

BELFAST, Northern Ireland, Sept. 14, 2021 /PRNewswire/ -- Cumulus Neuroscience (Cumulus, The Company), a leading global innovator providing real-world clinical trial data and AI-powered insights to accelerate the development of life-changing CNS therapies, announces that Dr Ruth McKernan CBE, a Founder and Director of the company, has been appointed as Chair.

Key Points: 
  • BELFAST, Northern Ireland, Sept. 14, 2021 /PRNewswire/ -- Cumulus Neuroscience (Cumulus, The Company), a leading global innovator providing real-world clinical trial data and AI-powered insights to accelerate the development of life-changing CNS therapies, announces that Dr Ruth McKernan CBE, a Founder and Director of the company, has been appointed as Chair.
  • Ruth's previous roles include Senior Vice President at Pfizer and Head of the Merck Neuroscience Research Centre.
  • Cumulus Neuroscience CEO Ronan Cunningham commented:"We are delighted that Ruth has agreed to become Chair of Cumulus Neuroscience.
  • Ruth McKernan, newly appointed Chair added: "The formation of Cumulus Neuroscience, represents a significant opportunity to address some of the current limitations of clinical trials in dementia and other brain disorders.